PDCD1 and neoplasm: It is well accepted that PD-L1 is expressed on many types of tumor cells, thus resulting in T cells exhaustion and immune escape of tumor cells [4, 6], so targeting PD-1/PD-L1 axis has achieved significant clinical benefits in multiple cancer types [25, 28, 29].